New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 5, 2014
08:36 EDTPTCTPTC Therapeutics named a new top pick at Credit Suisse
Credit Suisse said PTC Therapeutics is a new top pick following the recent CHMP recommendation. The firm expects PTC to launch Translarna in the EU in 2H and and views it as a potential billion-dollar drug. Shares are Outperform rated with a $40 price target.
News For PTCT From The Last 14 Days
Check below for free stories on PTCT the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 22, 2014
10:35 EDTPTCTPTC Therapeutics management to meet with Roth Capital
Subscribe for More Information
September 17, 2014
08:04 EDTPTCTPTC Therapeutics prepares launch of Translarna in Europe
Subscribe for More Information
September 15, 2014
09:59 EDTPTCTOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: American Realty (ARCP) initiated with an Overweight at JPMorgan... Athlon Energy (ATHL) initiated with a Buy at KLR Group... Capital Product (CPLP) initiated with a Buy at Jefferies... Continental Resources (CLR) initiated with a Buy at Canaccord... Costco (COST) initiated with a Buy at Citigroup... Infinera (INFN) initiated with an Outperform at Barrington... NRG Yield (NYLD) initiated with an Outperform at RBC Capital... PTC Therapeutics (PTCT) initiated with a Buy at Deutsche Bank... Power Solutions (PSIX) initiated with an Outperform at Northland... ServiceNow (NOW) initiated with an Outperform at William Blair... Target (TGT) initiated with a Neutral at Citigroup... Team (TISI) initiated with a Neutral at Sidoti... VeriFone (PAY) initiated with a Buy at Monness Crespi... Wal-Mart (WMT) initiated with a Neutral at Citigroup... Whiting Petroleum (WLL) initiated with a Buy at Canaccord... Winnebago (WGO) initiated with an Outperform at BMO Capital.
05:45 EDTPTCTPTC Therapeutics initiated with a Buy at Deutsche Bank
Target $75.
September 9, 2014
08:07 EDTPTCTPTC Therapeutics completes enrollment of Phase 3 trial of Translarna
PTC Therapeutics announced that it has completed enrollment of ACT DMD, the Phase 3 confirmatory trial of Translarna, or ataluren, for patients with nonsense mutation Duchenne muscular dystrophy, or nmDMD. Top-line data from the trial is expected in the second half of 2015 and will support further approvals globally, following European approval received earlier this year.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use